Heart Failure With Preserved Ejection Fraction

Cardiovascular
7
Pipeline Programs
11
Companies
12
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
5
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
Empagliflozin 10 MGPhase 41 trial
Active Trials
NCT05139472Completed8Est. Feb 2024
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
CDR132LPhase 21 trial
Active Trials
NCT05953831Withdrawn0Est. Sep 2025
Rivus Pharmaceuticals
Rivus PharmaceuticalsVA - Charlottesville
1 program
1
HU6Phase 21 trial
Active Trials
NCT05284617CompletedEst. May 2024
Cardurion Pharmaceuticals
1 program
1
IMR-687Phase 21 trial
Active Trials
NCT05312021WithdrawnEst. Nov 2023
Akebia Therapeutics
Akebia TherapeuticsCAMBRIDGE, MA
1 program
1
IW-1973Phase 21 trial
Active Trials
NCT03254485CompletedEst. Aug 2019
Palatin Technologies
1 program
1
PL-3994 Aqueous Intravenous Solution Dose AscentionPhase 21 trial
Active Trials
NCT04318145TerminatedEst. Dec 2023
35Pharma
35PharmaQC - Montreal
1 program
1
HS135Phase 11 trial
Active Trials
NCT06581159Terminated4Est. Jul 2025
Rhythm Pharmaceuticals
2 programs
Pacemaker PLR + TRT ONN/A1 trial
Rate Adaptive PacingN/A1 trial
Active Trials
NCT05839730Recruiting105Est. Jul 2027
NCT03160625Withdrawn0Est. May 2018
Pfizer
PfizerNEW YORK, NY
1 program
Physical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF PatientsN/A1 trial
Active Trials
NCT04998877Recruiting60Est. Jul 2026
GS
Gilead SciencesFOSTER CITY, CA
1 program
RanolazineN/A1 trial
Active Trials
NCT01505179Completed10Est. Jan 2015
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Targeted intervention based on risk factorsN/A1 trial
Active Trials
NCT06532019Not Yet RecruitingEst. Aug 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Boehringer IngelheimEmpagliflozin 10 MG
Novo NordiskCDR132L
Rivus PharmaceuticalsHU6
Cardurion PharmaceuticalsIMR-687
Palatin TechnologiesPL-3994 Aqueous Intravenous Solution Dose Ascention
Akebia TherapeuticsIW-1973
35PharmaHS135
Rhythm PharmaceuticalsPacemaker PLR + TRT ON
City TherapeuticsTargeted intervention based on risk factors
PfizerPhysical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients
Rhythm PharmaceuticalsRate Adaptive Pacing
Gilead SciencesRanolazine

Clinical Trials (12)

Total enrollment: 187 patients across 12 trials

NCT05139472Boehringer IngelheimEmpagliflozin 10 MG

Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction

Start: Nov 2021Est. completion: Feb 20248 patients
Phase 4Completed
NCT05953831Novo NordiskCDR132L

Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy

Start: Apr 2024Est. completion: Sep 20250
Phase 2Withdrawn
NCT05284617Rivus PharmaceuticalsHU6

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

Start: Oct 2022Est. completion: May 2024
Phase 2Completed
NCT05312021Cardurion PharmaceuticalsIMR-687

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction

Start: Apr 2022Est. completion: Nov 2023
Phase 2Withdrawn
NCT04318145Palatin TechnologiesPL-3994 Aqueous Intravenous Solution Dose Ascention

Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects

Start: Nov 2020Est. completion: Dec 2023
Phase 2Terminated
NCT03254485Akebia TherapeuticsIW-1973

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Start: Nov 2017Est. completion: Aug 2019
Phase 2Completed
NCT0658115935PharmaHS135

Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Start: Jan 2025Est. completion: Jul 20254 patients
Phase 1Terminated
NCT05839730Rhythm PharmaceuticalsPacemaker PLR + TRT ON

Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction

Start: Sep 2024Est. completion: Jul 2027105 patients
N/ARecruiting
NCT06532019City TherapeuticsTargeted intervention based on risk factors

Clinical Study of Active Intervention in High-risk HFpEF Patients

Start: Aug 2024Est. completion: Aug 2028
N/ANot Yet Recruiting
NCT04998877PfizerPhysical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients

Physical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients

Start: Aug 2021Est. completion: Jul 202660 patients
N/ARecruiting
NCT03160625Rhythm PharmaceuticalsRate Adaptive Pacing

Evaluation of Rate Adaptive Pacing on Chronotropic Response in Preserved Ejection Fraction HF

Start: Jul 2017Est. completion: May 20180
N/AWithdrawn
NCT01505179Gilead SciencesRanolazine

The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction

Start: Feb 2011Est. completion: Jan 201510 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
19h ago
From $150K/yr

Clinical Consultant

Johnson & Johnson
North Ryde, New South Wales, Australia
20h ago

Regional Sales Specialist (Orange County / Long Beach, CA) - Johnson & Johnson MedTech, Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
20h ago
$100K - $135K/yr

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
20h ago

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
20h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 187 patients
11 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)